AVITA Medical stock raises 2026 revenue guidance after Q2 beat

Published on 10/07/2026 at 04:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AVITA Medical reported USD 21.70 million in Q2 revenue against USD 20.25 million consensus on August 6, 2026. RCEL was last at USD 12.99 on October 6.

RCEL, AU000000AVH4, Illustration mit AI erstellt.

AVITA Medical (AU000000AVH4) reported Q2 2026 revenue of USD 21.70 million against USD 20.25 million consensus, while its adjusted loss of USD 0.25 per share was narrower than the USD 0.29 estimate, according to MarketBeat on September 13, 2026. The result gives the stock a concrete test as management works to convert stronger demand into cash generation.

Revenue beats consensus

The Q2 revenue figure exceeded consensus by USD 1.45 million, or 7.16 percent, and represented 18 percent year-over-year growth, according to RTTNews on October 5, 2026. AVITA markets RECELL for thermal burn and trauma wounds alongside Cohealyx and PermeaDerm, giving the company three commercial product lines in acute wound care.

Management also expects cash flow breakeven in Q4 2026 after second-quarter cash burn fell to USD 3.2 million. The forecast depends on sequential revenue growth and operating discipline rather than a rapid expansion of the sales organization.

Guidance moves higher

At the Morgan Stanley healthcare conference on September 16, 2026, AVITA raised 2026 revenue guidance to USD 86 million to USD 89 million from USD 80 million to USD 85 million, as reported by Investing.com. The new range implies growth of 20 percent to 24 percent against 2025 revenue of USD 71.6 million, but the company still has to demonstrate that reimbursement and execution improvements can persist.

Analyst expectations remain constructive but sit below the latest market quote. MarketBeat reported a Moderate Buy consensus from seven analysts on September 13, 2026, with five Buy ratings, one Hold, one Sell and an average 12-month price target of USD 11.40. The individual targets listed by the outlet ranged from USD 11.00 to USD 14.00.

RCEL trades below its yearly high

RCEL was last at USD 12.99 on Nasdaq on October 6, 2026, down USD 0.26, or 1.96 percent, from the prior close. The session range was USD 12.39 to USD 13.49, the 52-week range was USD 3.22 to USD 13.49, trading volume was 408,674 shares and market capitalization was USD 322.7 million.